Lymphoma, Follicular
77
4
10
39
Key Insights
Highlights
Success Rate
72% trial completion
Published Results
28 trials with published results (36%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
19.5%
15 terminated out of 77 trials
72.2%
-14.3% vs benchmark
13%
10 trials in Phase 3/4
72%
28 of 39 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 39 completed trials
Clinical Trials (77)
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 )
A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies
Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
A Phase 1 Study of ADI-001 in B Cell Malignancies
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.
PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma